In terms of treating latent tuberculosis infection, what is the regimen for INH-sensitive patients?

The recommended regimen for treating latent tuberculosis infection (LTBI) in INH-sensitive patients is Isoniazid (INH) combined with Pyridoxine for a duration of 9 months. This approach is effective because INH is potent against Mycobacterium tuberculosis and helps prevent the development of active tuberculosis from latent infection. Pyridoxine is often co-administered with INH to prevent peripheral neuropathy, a potential side effect associated with INH use, particularly in individuals at risk.

The 9-month regimen is supported by guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), which recommend it as a standard approach for those who are at increased risk of progression from latent to active TB, such as individuals with compromised immune systems.

While other options may represent alternative treatments for tuberculosis or other conditions, they are not the standard regimens for INH-sensitive latent tuberculosis infection. For example, a 4-month course of Rifampin may be considered in certain cases, such as for individuals who are INH-resistant or when INH cannot be used. A 6-month course of INH is less common for LTBI and does not provide the optimal duration recommended for those with latent